4DMT Reports Full Year 2023 Financial Results and Operational Highlights
We currently expect cash and cash equivalents to be sufficient to fund operations into the first half of 2027.
- We currently expect cash and cash equivalents to be sufficient to fund operations into the first half of 2027.
- R&D Expenses: Research and development expenses were $97.1 million for 2023, as compared to $80.3 million for 2022.
- G&A Expenses: General and administrative expenses were $36.5 million for 2023, as compared to $32.9 million for 2022.
- Net Loss: Net loss was $100.8 million for 2023, as compared to net loss of $107.5 million for 2022.